44 results about "Glandular Epithelial Cells" patented technology

The invention relates to the technical field of small molecule medicines, in particular to a medicine for improving chronic atrophic gastritis and application of the medicine. The invention aims to provide a compound, a pharmaceutical composition containing the compound and application of the compound, the 9, 13-substituted berberine derivative has a good improvement effect on CAG, and further research and observation of the compound on treatment of CAG gastric mucosa gland epithelial cell atrophy, gastric mucosa thinning, gastric mucosa epithelial cell atrophy, gastric mucosa hyperplasia, gastric mucosa epithelial cell atrophy and gastric mucosa hyperplasia. The 9, 13-substituted berberine derivative disclosed by the invention can be used for preventing and / or treating CAG (chorionic gonadotrophin) by virtue of the inhibition effects on infiltration adhesion of a large number of neutrophils and lymphocytes, inflammatory factors and the like.

The invention discloses a new application of human YTHDF1, namely an application of a human YTHDF1 gene expression quantity detection reagent in preparation of a prostatic cancer clinical diagnosis reagent. The expression of the human YTHDF1 gene in prostatic cancer tissues and cell lines is increased; after the expression of the YTHDF1 gene is knocked down, the growth of a prostate cancer cell line, the culture of organoids and the growth of transplanted tumors in nude mice are obviously inhibited; according to the present invention, with the application of the RNF7 in the tumor cells, the proliferation of the normal prostate epithelial cells can be promoted by the overexpression, the protein level of the RNF7 in the YTHDF1 knocked-down cells is significantly inhibited, the phenotype of the YTHDF1 knocked-down cells can be rescued by the overexpression of the RNF7, and the sensitivity of the tumor cells to the chemotherapeutic drugs can be promoted by the YTHDF1 knocked-down cells so as to promote the apoptosis; the prostatic cancer can be treated by inhibiting expression drugs of the human YTHDF1 gene, inhibiting expression of the E3 ubiquitin ligase RNF7 gene or screening drugs for degrading the E3 ubiquitin ligase RNF7.

The invention provides an application of protocatechuic acid in an anti-inflammatory active pharmaceutical composition in dairy cow mammary epithelial cells, belongs to the technical field of bioengineering, and aims to obtain high-purity protocatechuic acid (greater than or equal to 95%) by optimizing a preparation process through the application of protocatechuic acid in inhibition of inflammatory response of dairy cow mammary epithelial cells. Under the concentration of 1-100 mu M, the level of inflammatory factors such as TNF-alpha, IL-6 and the like is remarkably reduced (the inhibition rate is larger than or equal to 60%), the mechanism is that NF-kB and MAPK signal channels are inhibited, cytotoxicity is avoided, and a milk region perfusion agent or a feed additive can be prepared to be used for preventing and treating dairy cow mastitis.

The invention relates to the technical field of biological medicine, and particularly discloses siRNA of a targeted RIG-I receptor gene and application of the siRNA, the siRNA is selected from any one of siRNA-1 and siRNA-3, the siRNA-1 comprises a positive-sense strand with the nucleotide sequence shown as SEQ ID NO.1 and an antisense strand with the nucleotide sequence shown as SEQ ID NO.2, and the siRNA comprises a positive-sense strand with the nucleotide sequence shown as SEQ ID NO.1 and a negative-sense strand with the nucleotide sequence shown as SEQ ID NO.2. The siRNA-3 comprises a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO.5 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO.6. The invention further discloses a preparation method of the siRNA-3. The siRNA provided by the invention is used for inhibiting expression of RIG-I receptor genes so as to reduce inflammatory response in a dairy cow mammary epithelial cell inflammation model, so that the siRNA provided by the invention can be used for preparing the medicine for treating dairy cow mastitis.

The invention belongs to the technical field of genetic engineering, and particularly relates to application of miRNA related to cow mastitis. The invention provides an application of miR-320b in preparation of a medicine for treating dairy cow mastitis, the nucleotide sequence of the miR-320b is shown as SEQ ID NO.1, and the miR-320b is used for diagnosing the process of resisting Escherichia coli, E. coli type dairy cow mastitis. The miR-320b expression quantity of the miR-320b in the dairy cow mammary epithelial cells or E. coli type mammary tissue induced by lipopolysaccharide (LPS) is detected, and when the expression quantity of the miR-320b is obviously reduced, the miR-320b is prompted to have an anti-inflammatory function in the dairy cow mastitis.

The invention discloses a novel compound and application thereof in preparation of a medicine for treating triple negative breast cancer. The invention provides a compound with a novel structure. Activity studies show that the compound has an excellent treatment effect on triple negative breast cancer, not only can inhibit growth and migration of triple negative breast cancer cells, but also can induce apoptosis of the triple negative breast cancer cells, has no obvious inhibition effect on normal mammary epithelial cells, and is superior to cis-platinum in safety. The invention also provides a method for preparing the compound, which is simple and feasible.

The invention discloses a method for increasing the passage frequency of a mammary epithelial cell line and application of the method, and belongs to the technical field of mammary epithelial cell lines. It is found for the first time that an insulator-stent attachment area exogenous fragment HS4-SAR fragment is connected with a p-Ef1a-SV40LT-Puro vector or a pEF1a-eGFP vector, commercial immortalized cell lines and primary cell lines are transfected, the passage number of mammary gland epithelial cell lines can be remarkably increased, and the mammary gland epithelial cell lines can be obtained. After 120 generations of passage, the cell morphology is still normal, malignant transformation is avoided, and the gene expression level is still not reduced, so that immortalization is realized; the established milk goat mammary gland epithelial cell line still has the capability of synthesizing and secreting protein; the provided method for increasing the passage frequency of the mammary epithelial cell line is simple and easy to operate, has a remarkable effect on an immortalized cell line and a primary cell line, and is expected to increase the passage frequency of stable passage of various mammary epithelial cell lines and reduce the cell cost of related research.

The present invention relates to the technical field of polyphenol extraction, and specifically discloses a mulberry bound polyphenol, its extraction method and application. The mulberry fruits are freeze-dried and crushed, and an 80% acetone solution is added at a solid-liquid ratio of 1:10 (w:v). After mixing, the supernatant is discarded by centrifugation. The precipitate is hydrolyzed with NaOH solution, neutralized with hydrochloric acid to neutrality, and then ethyl acetate is added continuously for extraction 5 times to obtain a crude extract of mulberry bound polyphenol. The mulberry bound polyphenol is obtained after purification by macroporous resin D101. The mulberry bound polyphenol extracted by the present invention can significantly inhibit the proliferation and viability of various cancer cells, and at the same time has no obvious effect on the growth of normal mammary epithelial cells and liver cells, and has antibacterial activity against Escherichia coli and Staphylococcus aureus. Therefore, it has application potential in the preparation of anti-tumor and antibacterial drugs.

The invention discloses a method for regulating and controlling the growth of mammary epithelial cells of milk goats based on a KLC1-chi-miR-423-5p-PDGFAceRNA network, and belongs to the field of animal molecular biology and cell biology. Through combination of transcriptome sequencing and functional verification, it is revealed for the first time that KLC1 can be used as ceRNA, and targeted inhibition of chi-miR-423-5p on PDGFA mRNA is effectively relieved through competitive combination of chi-miR-423-5p, so that proliferation of mammary epithelial cells is promoted, and apoptosis is inhibited. The research results of the invention not only fill the blank of research on the regulation and control mechanism of the breast epithelial cell ceRNA network of the milk goat, but also provide a theoretical basis for breast development regulation and control, tissue repair and prevention and treatment of related diseases, and lay an important foundation for developing a potential molecular intervention strategy.

The invention relates to the technical field of cells, and particularly discloses an amino acid culture medium for promoting synthesis of casein of dairy cow mammary cells and a preparation method. In the culture medium, the addition amount of lysine is 0.74 mmol / L, the addition amount of threonine is 0.22 mmol / L, and the addition amount of phenylalanine is 0.28 mmol / L. Tests prove that the culture medium under the condition of the application can obviously improve the relative proliferation rate and casein expression quantity of dairy cow mammary gland cells compared with a culture medium under 4 times of plasma concentration (optimal amino acid supply mode) of dairy cow. The method for promoting casein synthesis comprises the following steps: culturing cow mammary epithelial cells to P3 generation; when the P3 generation cells grow to 75-85% of the adherent area in a 75 cm < 3 > culture flask, transferring the P3 generation cells into a culture medium without lysine, threonine and phenylalanine, and starving for 16 hours; when the cells are hungry, transferring the cells into the culture medium prepared by the invention to be continuously cultured for 24 hours; and after culture is finished, measuring the relative proliferation rate and casein expression quantity of the cells.

The present disclosure provides methods of manufacturing cell-laden scaffolds comprising lipid-producing cells comprising confining lipid-producing precursor cells in a three-dimensional (3D) environment and culturing the lipid- producing precursor cells confined in the 3D environment in a food-grade differentiation medium to obtain the cell-laden scaffold comprising lipid-producing cells. In one embodiment, the 3D environment is formed by a mixture comprising lipid-producing precursor cells and a food-grade polymericsolution, wherein the food-grade polymeric solution comprises one or more selected from the group consisting of alginate, gelatin, pectin, agarose, carrageenan, gellan gum, konjac glucomannan, cellulose, etc. and combinations thereof, the lipid-producing precursor cells are selected from the group consisting of adipose-derived stem cells, preadipocytes mesenchymal stem cells, embryonic stem cells, induced- pluripotent stem cells and combinations thereof, the lipid-producing cells are selected from adipocytes, hepatocytes, sebocytes, mammary epithelia cells, keratinocytes and combinations thereof, and the food-grade differentiation medium comprises a fatty acid.

The present invention provides an application of Forskolin in promoting mammary epithelial cells to synthesize sialic acid, and relates to the field of biotechnology. The inventors have proved through experiments that the use of Forskolin to treat mammary epithelial cells can significantly promote the content of sialic acid in cell culture fluid. It has been proved that Forskolin can promote mammary epithelial cells to synthesize sialic acid. A new way to regulate sialic acid secretion is provided.

The invention discloses application of MISP as a breast cancer diagnosis / prognosis marker and a treatment target. The in-depth study on the expression of MISP in breast cancer cells and the influence on malignant biological behaviors such as breast cancer proliferation shows that compared with normal breast epithelial cells, the MISP is highly expressed in the breast cancer cells, the expression of the MISP is highly related to poor clinical prognosis of breast cancer patients, and the proliferation of the breast cancer cells can be inhibited by reducing the expression of the MISP. A new biomarker is provided for diagnosis and prognosis of the breast cancer, a new target spot is provided for treatment of the breast cancer, and important scientific significance is achieved in the aspects of subsequent drug research and development, clinical treatment and the like.

The present disclosure provides thymic cells, thymic organoids, and animal models comprising such thymic cells and thymic organoids. The present disclosure also provides methods for inducing, in vitro and in vivo, differentiation of pluripotent stem cells into definitive endoderm (DE), anterior and anterior intestinal endoderm (AFE), ventral pharyngeal endoderm (VPE), thymic epithelial progenitor (TEP) cells, thymic epithelial cells (TEC), and thymic organoid.

The application discloses a method for improving the passaging times of a mammary epithelial cell line and application thereof, and belongs to the technical field of mammary epithelial cell lines. The application first finds that the exogenous fragment HS4-SAR fragment in the attachment area of the insulator-scaffold is connected with a p-Ef1a-SV40LT-Puro vector or a pEF1a-eGFP vector, and the transfection of commercial immortalized cell lines and primary cell lines can significantly improve the passaging times of the mammary epithelial cell lines, the cell morphology is still normal after 120 generations, the malignant transformation does not occur, the gene expression level does not decrease, and the immortalization is realized; the established goat mammary epithelial cell line still has the ability of synthesizing and secreting proteins; the method for improving the passaging times of the mammary epithelial cell line is simple and easy to operate, has a significant effect on the immortalized cell lines and the primary cell lines, and is expected to improve the stable passaging times of various mammary epithelial cell lines, and reduce the cell cost of related research.

The invention discloses a gene editing system for developing a Staphylococcus aureus mastitis resistant Holstein cow aiming at an ADAM10 gene and application of the gene editing system. According to the invention, a novel single-base gene editing ABE technology is used to carry out gene editing on dairy cow fibroblasts, amino acids at main action sites of cell surface receptors ADAM10 of alpha-hemolysin are mutated, and the affinity activity between the two is reduced. Experiments prove that compared with a wild type, the inflammatory sensitivity of the mutated cow mammary epithelial cells to alpha-hemolysin is greatly reduced. Then, gene editing individuals are cultivated through cell nucleus transfer and embryo transfer technologies, and the mastitis resistance of the individuals is achieved.

The invention provides a 5 alpha-reductase inhibitor. The inhibitor is pawpaw total triterpenes (TCS). The invention also provides application of the pawpaw total triterpenes TCS in preparation of drugs for treating benign prostatic hyperplasia. TCS and UA have no obvious toxic and side effects on visceral organs of each group of rats; the thickness of glandular epithelial cells in a TCS group is remarkably reduced, the 5AR activity of the TCS group is remarkably reduced, the T level is remarkably reduced, and the DTH level is remarkably reduced; the blood sugar of the TCS group is obviously reduced, the concentration of total cholesterol and low-density lipoprotein is obviously reduced, and the TCS can obviously increase the high-density lipoprotein level and reduce the content of triglyceride. The results show that the TCS and the main component tartaric acid have a remarkable inhibiting effect on prostatic hyperplasia. The inhibition of 5AR activity and the reduction of DHT generation and T content are one of the action mechanisms, and the important characteristic is that the prostatic hyperplasia can be inhibited and abnormal blood sugar and blood fat can be regulated at the same time.

The application relates to the technical field of biology, and discloses a method for inducing a cell line of immortalized musk deer scent glands to synthesize dihydrotestosterone, wherein the cell line is obtained by transfecting a primary musk deer scent gland epithelial cell with a lentivirus carrying an SV40 Large T antigen and performing resistance screening; the cell line is in an epithelial cell form and stably expresses keratin 18, cholesterol side chain cleavage enzyme, 17 alpha-hydroxylase and 3 beta-hydroxysteroid dehydrogenase. Through lentivirus-mediated SV40 Large T antigen transfection, the primary musk deer scent gland epithelial cell breaks through the limit of replicative senescence and obtains unlimited proliferation capacity, effectively overcomes the defects that the primary cell is prone to fibrosis and rapidly loses metabolic function during in-vitro culture, provides a standardized cell model with a clear genetic background and persistent metabolic activity for biological manufacturing of dihydrotestosterone, and relieves the dependence on endangered animal live resources.

The invention relates to the technical field of molecular biology, in particular to an MUC15 gene segment, expression vector construction of the MUC15 gene segment and an expression vector transfection method of the MUC15 gene segment, and the nucleotide sequence of the MUC15 gene segment influencing buffalo mammary epithelial cell triglyceride and fatty acid synthesis is shown as SEQ No.1. The MUC15 gene segment is obtained by amplifying a primer pair, and the primer pair is used for amplifying the buffalo mammary epithelial cell triglyceride and fatty acid synthesis. The primer pair is specifically as follows: F: 5 '-AGTCCGGACTCAGATCTCGAGATGTTGACTCAGCCAAAATTCTG-3', F: 5 '- And R: 5 '-AATTCGAAGCTTGAGCTCGAGCTTACACGAAGTGGAGG-3'. Compared with the prior art, the buffalo mammary epithelial cell MUC15 gene fragment influencing the synthesis of triglyceride and fatty acid in the buffalo mammary epithelial cell is obtained, and a pEGFP-C1-MUC15 eukaryotic expression vector is constructed and transfected to the buffalo mammary epithelial cell, so that the synthesis of triglyceride by the buffalo mammary epithelial cell is promoted, and the milk fat content in buffalo milk is increased.

The invention discloses a 17-hydroxy-jolkinolide B (HJB) coupled triphenylphosphine derivative as well as a preparation method and application thereof, and belongs to the technical field of antitumor drugs, the 17-hydroxy-jolkinolide B coupled triphenylphosphine derivative has the following structural formula: # imgabs0 #, and n is equal to 1-3. According to the invention, an effective component HJB extracted from euphorbia fischeriana is taken as a raw material, triphenylphosphine cations are introduced to C-17 site of HJB through esterification reaction and substitution reaction, and in-vivo and in-vitro antitumor activity evaluation of a novel derivative is carried out through an MTT method, laser confocal microscopy observation, flow cytometry and an animal transplantation tumor method. It is found that the novel derivative has relatively low toxicity to human normal mammary epithelial cells MCF-10A while retaining relatively good anti-tumor activity to human liver cancer HepG-2, human breast cancer MDA-MB-231, human lung cancer H1975 and human gastric cancer MNK45 cells, and can obviously inhibit growth of transplanted tumors in Balb / c mice. The 17-hydroxy-jolkinolide B coupled triphenylphosphine derivative disclosed by the invention has the potential of being developed into a new anti-tumor drug.

A method of producing mammalian breast milk exosomes, such as human breast milk exosomes, comprising generating lactating cells derived from mammalian breast epithelial cells, such as human breast epithelial cells, expressing mammalian milk-like products, such as human milk-like products, from the lactating cells, and purifying the exosomes from the mammalian milk-like products.

The present invention provides a thymic epithelial cell production method, the method including a step for culturing thymic epithelial progenitor cells for a long period of time. The present invention also provides a transplant therapeutic agent that includes thymic epithelial cells produced by the production method according to the present invention. The present invention further provides a T cell production method, the method including a feature of causing thymic epithelial cells produced by the production method according to the present invention to contact hematopoietic stem cells or any cells in the process of differentiation from hematopoietic stem cells to T cells.

The present invention relates to the field of small molecule drug technology, and more specifically to a drug for ameliorating chronic atrophic gastritis and its use. One object of the present invention is to provide a compound, a pharmaceutical composition comprising the compound, and its use. The 9- and 13-substituted berberine derivatives of the present invention have a significant ameliorative effect on CAG. Further studies and observations have shown that the compounds inhibit CAG symptoms, such as atrophy of gastric mucosal glandular epithelial cells, thinning of the gastric mucosa, infiltration and adhesion of large numbers of neutrophils and lymphocytes, and inflammatory factors. It was found that the 9- and 13-substituted berberine derivatives of the present invention can be used to prevent and / or treat CAG.

The invention provides a reagent for activating beta-casein expression, a recombinant mammary epithelial cell, a method for increasing the content of beta-casein in milk and application, and belongs to the technical field of genetic engineering. The invention provides a reagent for activating beta-casein expression, which comprises dCas9 protein or a dCas9 protein expression vector, and also comprises sgRNA of a targeted beta-casein coding gene or a gene derivative product containing the sgRNA, the nucleotide sequence of the sgRNA is as shown in SEQ ID NO: 1. The dCas9 is combined with sgRNA of a targeted beta-casein coding gene, so that the expression of a target gene can be activated. Results of the embodiment of the invention show that when the reagent is transferred into bovine mammary epithelial cells, the CSN2 gene RNA expression quantity and beta-casein expression quantity can be increased, the effect is stable, and the reagent can be used for constructing a cell line for stably expressing beta-casein for a long time and can be used on a large scale in production practice.

The invention discloses an application of GW9508 in preparation of a product for improving thymus function degeneration caused by aging, in-vivo and in-vitro experiments prove that the GW9508 can improve the aging state of thymus epithelial cells, promote the activity of the aging thymus epithelial cells, increase the thymus index of an aging mouse, increase the number of the thymus epithelial cells and subpopulation cells of the thymus epithelial cells and improve the thymus function degeneration caused by aging. The GW9508 has the advantages that the GW9508 can be used for improving the thymus function of an aged mouse, enhancing the thymus cell maturation tending capacity of the GW9508, increasing the number of thymus cells and subgroups of the thymus cells, and having an outcome effect on thymus of the aged mouse, so that the GW9508 can improve the thymus function of the aged mouse by improving the aging of the thymus, and the GW9508 can be used for preparing a product for improving thymus function degradation caused by aging.

The invention discloses an immortalized egg shell gland epithelial cell line and application thereof. The invention belongs to the technical field of biology, and particularly relates to an immortalized egg shell gland epithelial cell line and application thereof. The construction method of the immortalized egg shell gland epithelial cell line comprises the following steps: 1) obtaining SV40 overexpression lentivirus; 2) transfecting the lentivirus obtained in the step 1) to chicken primary eggshell gland epithelial cells; amplifying the transfected cells for 3-4 generations, and screening puromycin to obtain successfully transfected eggshell gland epithelial cells; and (3) carrying out subculture on the successfully transfected eggshell gland epithelial cells obtained in the step (2) to obtain the stably subcultured immortalized eggshell gland epithelial cells. The immortalized egg shell gland epithelial cell provided by the invention can provide a reliable cell model for researching related functions of poultry egg shell glands, and has an important value for developing a novel feed additive capable of improving chicken genital tract health and egg shell quality.

The invention belongs to the technical field of biology, and particularly relates to application of baicalin to preparation of a product for promoting milk fat synthesis of cow mammary epithelial cells. Researches show that baicalin can promote expression of milk fat synthesis related genes in bMECs and formation of lipid droplets, then milk fat synthesis is promoted, and the influence of oxidative stress on milk fat synthesis of bMECs is relieved. In addition, baicalin can promote the level of key protein in milk fat synthesis in bMECs.

This disclosure provides thymocytes, thymic organoids, and animal models comprising such thymocytes and thymic organoids. It also provides methods for inducing the differentiation of pluripotent stem cells into endoderm (DE), anterior foregut endoderm (AFE), ventral pharyngeal endoderm (VPE), thymic epithelial precursor (TEP) cells, thymic epithelial cells (TEC), and thymic organoids in vitro and in vivo.

The invention relates to the technical field of biological medicines, in particular to application of beta-aminoisobutyric acid in preparation of a preparation for treating animal mastitis. The invention discloses application of beta-aminoisobutyric acid in preparation of a preparation for treating animal mastitis. The beta-aminoisobutyric acid provided by the invention is derived from the posterior intestine content of the healthy saanen milk goat with the lowest somatic cell count in the milk obtained by large group screening. According to the present invention, the proliferation efficiency of dairy cow mammary epithelial cells can be significantly promoted, and the expression of the related proteins involved in the endoplasmic reticulum protein quality control pathway can be promoted in the LPS-induced dairy cow mammary epithelial cell inflammation model so as to enhance the folding efficiency of the proteins during the inflammation process; the removal of mistakenly folded and unfolded proteins is accelerated, and finally, the concentration of proinflammatory cytokines is reduced, and the concentration of anti-inflammatory cytokines is increased, so that the inflammatory phenotype is relieved.

The invention relates to the technical field of molecular biology, in particular to an ACSL3 gene segment, an expression vector construction method thereof and an expression vector transfection method thereof, the nucleotide sequence of the ACSL3 gene segment influencing buffalo mammary epithelial cell triglyceride and fatty acid synthesis is shown as SEQ No.1, the ACSL3 gene segment is obtained by amplifying a primer pair, and the primer pair has a nucleotide sequence shown as SEQ No.2. The primer pair is specifically as follows: F: 5 '-AGTCCGGACTCAGATCTCGAGATGAATAACCAGGGTCTACAA-3', F: 5 '-AG: 5'-AG: 5 '-AG: 5'-AG: 5 '-AG: 5'-AG: 5 ' And R: 5 '-AATTCGAAGCTTGAGCTATGAGCTATTTTCTTCCATATTCGCTCA-3'. Compared with the prior art, the ACSL3 gene fragment influencing the synthesis of the buffalo mammary epithelial cell triglyceride and fatty acid is obtained, and a pEGFP-C1-ACSL3 eukaryotic expression vector is constructed and transfected to the buffalo mammary epithelial cell, so that the synthesis of the triglyceride by the buffalo mammary epithelial cell is promoted, and the milk fat content in buffalo milk is increased.